Adverum Biotechnologies (ADVM) Competitors $2.45 -0.07 (-2.78%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.48 +0.02 (+1.02%) As of 08/7/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. RAPT, MDWD, TLSA, ELDN, DMAC, YMAB, NLTX, CRBU, FDMT, and ALMSShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Rapt Therapeutics (RAPT), MediWound (MDWD), Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), DiaMedica Therapeutics (DMAC), Y-mAbs Therapeutics (YMAB), Neoleukin Therapeutics (NLTX), Caribou Biosciences (CRBU), 4D Molecular Therapeutics (FDMT), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Rapt Therapeutics MediWound Tiziana Life Sciences Eledon Pharmaceuticals DiaMedica Therapeutics Y-mAbs Therapeutics Neoleukin Therapeutics Caribou Biosciences 4D Molecular Therapeutics Alumis Adverum Biotechnologies (NASDAQ:ADVM) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Which has preferable earnings & valuation, ADVM or RAPT? Rapt Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M51.18-$130.93M-$6.40-0.38Rapt Therapeutics$1.53M110.81-$129.87M-$19.20-0.53 Do analysts rate ADVM or RAPT? Adverum Biotechnologies currently has a consensus price target of $23.80, suggesting a potential upside of 871.43%. Rapt Therapeutics has a consensus price target of $20.57, suggesting a potential upside of 100.70%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Rapt Therapeutics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57 Is ADVM or RAPT more profitable? Rapt Therapeutics' return on equity of -81.47% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -130.53% -66.31% Rapt Therapeutics N/A -81.47%-70.24% Does the media favor ADVM or RAPT? In the previous week, Rapt Therapeutics had 2 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 3 mentions for Rapt Therapeutics and 1 mentions for Adverum Biotechnologies. Rapt Therapeutics' average media sentiment score of 0.77 beat Adverum Biotechnologies' score of 0.00 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapt Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ADVM or RAPT? 48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are owned by institutional investors. 6.0% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 2.4% of Rapt Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, ADVM or RAPT? Adverum Biotechnologies has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. SummaryAdverum Biotechnologies and Rapt Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.65M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-0.3817.9729.8925.14Price / Sales51.18262.52421.4486.79Price / CashN/A41.8335.9458.58Price / Book0.727.238.125.59Net Income-$130.93M-$54.43M$3.26B$265.48M7 Day Performance5.60%0.22%0.69%1.22%1 Month Performance2.08%5.59%2.48%0.39%1 Year Performance-64.60%9.98%27.93%23.47% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.0606 of 5 stars$2.45-2.8%$23.80+871.4%-63.7%$52.65M$1M-0.38190Upcoming EarningsRAPTRapt Therapeutics4.1478 of 5 stars$12.67-4.8%$21.67+71.0%-46.8%$220.09MN/A-0.6680MDWDMediWound2.1759 of 5 stars$19.93-2.0%$32.25+61.8%+14.9%$219.72M$20.22M-9.5480Upcoming EarningsGap UpTLSATiziana Life Sciences0.2821 of 5 stars$1.95+4.8%N/A+49.3%$217.34MN/A0.008ELDNEledon Pharmaceuticals1.6755 of 5 stars$3.23-10.8%$10.00+209.6%+5.4%$216.77MN/A-1.5410Gap DownHigh Trading VolumeDMACDiaMedica Therapeutics1.4397 of 5 stars$5.06+0.2%$10.75+112.5%+48.3%$216.56MN/A-7.9120Upcoming EarningsYMABY-mAbs Therapeutics2.2872 of 5 stars$4.88+2.3%$15.60+219.7%-22.5%$216M$87.68M-7.63150Trending NewsUpcoming EarningsAnalyst DowngradeNLTXNeoleukin TherapeuticsN/A$22.72-0.4%N/A-43.8%$213.52MN/A-7.3190CRBUCaribou Biosciences2.4543 of 5 stars$2.29+0.4%$8.50+271.2%-4.7%$212.05M$9.99M-1.41100Gap UpFDMT4D Molecular Therapeutics2.5044 of 5 stars$4.64+1.5%$29.56+537.0%-60.7%$211.70M$40K-1.46120ALMSAlumis2.0316 of 5 stars$4.04+4.1%$19.80+390.1%-64.4%$211.09MN/A0.00N/AUpcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies RAPT Alternatives MDWD Alternatives TLSA Alternatives ELDN Alternatives DMAC Alternatives YMAB Alternatives NLTX Alternatives CRBU Alternatives FDMT Alternatives ALMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.